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Abstract
Background: The R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly
increases the risk for late onset Alzheimer’s disease. Mouse models accurately reproducing phenotypes observed in
Alzheimer’ disease patients carrying the R47H coding variant are required to understand the TREM2 related
dysfunctions responsible for the enhanced risk for late onset Alzheimer’s disease.
Methods: A CRISPR/Cas9-assisted gene targeting strategy was used to generate Trem2 R47H knock-in mice. Trem2
mRNA and protein levels as well as Trem2 splicing patterns were assessed in these mice, in iPSC-derived human
microglia-like cells, and in human brains from Alzheimer’s patients carrying the TREM2 R47H risk factor.
Results: Two independent Trem2 R47H knock-in mouse models show reduced Trem2 mRNA and protein
production. In both mouse models Trem2 haploinsufficiency was due to atypical splicing of mouse Trem2 R47H,
which introduced a premature stop codon. Cellular splicing assays using minigene constructs demonstrate that the
R47H variant induced abnormal splicing only occurs in mice but not in humans. TREM2 mRNA levels and splicing
patterns were both normal in iPSC-derived human microglia-like cells and patient brains with the TREM2 R47H
variant.
Conclusions: The Trem2 R47H variant activates a cryptic splice site that generates miss-spliced transcripts leading
to Trem2 haploinsufficiency only in mice but not in humans. Since Trem2 R47H related phenotypes are mouse
specific and do not occur in humans, humanized TREM2 R47H knock-in mice should be generated to study the
cellular consequences caused by the human TREM2 R47H coding variant. Currently described phenotypes of Trem2
R47H knock-in mice can therefore not be translated to humans.
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Background
Microgliosis has long been thought to play a central role
in the initiation and progression of Alzheimer’s disease
(AD) pathology. Indeed, genetic analyses recently re-
vealed risk variants in a number of genes exclusively or
at least preferentially expressed in microglia [1–5].
Among these, the gene encoding the triggering receptor
expressed on myeloid cells 2 (TREM2) plays a pivotal
role in regulating microglial activity [6–9]. As part of the
disease associated signature of microglia (DAM; also
called MGnD (microglia neurodegenerative disease)),
TREM2 is one of the most upregulated genes when
microglia encounter acute injuries within the brain or
respond to neurodegenerative disorders such as AD and
amyotrophic lateral sclerosis [6, 10]. Moreover, absence
of functional TREM2 caused by a gene knockout or cer-
tain disease-associated sequence variants, which misfold
TREM2 and retain the protein within the endoplasmic
reticulum, lock microglia in a homeostatic state and
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prevent their activation in vivo [7, 11]. As a consequence
cellular defense mechanisms such as chemotaxis, prom-
inently visible by the lack of clustering around amyloid
plaques, proliferation, phagocytosis of dead cells and
amyloid fibrils are all reduced [8, 12, 13]. Furthermore,
overexpression of human wild-type (wt) TREM2 in a
Trem2 knockout mouse corrects loss-of-function pheno-
types [14]. Thus TREM2 is believed to have protective
functions. In line with that, TREM2 is upregulated early
during disease development. In a study on patients with
dominantly inherited AD (DIAN), soluble TREM2 was
found to be increased 5 years before onset of clinical
symptoms, which may also be interpreted as a protective
response [15]. Consistent with this conclusion, lack of
functional TREM2 affects amyloid plaque morphology and
increases plaque associated neuritic dystrophies [13, 16].
Furthermore, in models of acute neuronal injury such as
the cuprizone model, Trem2 activity facilitates clearance
of cellular debris and recovery [11, 17, 18]. For tauopathies
there are, however, opposing results indicating either pro-
tective or detrimental functions [19, 20]. In line with find-
ings in mouse models for amyloid plaque pathology, this
may be due to stage specific functions of Trem2.
Mouse models and cellular systems greatly helped to
understand the consequences of loss-of-function muta-
tions / haploinsufficiency of TREM2. However, the most
important disease variant, namely R47H, which has been
shown to increase the risk for late onset AD to a similar
extent as the Apo lipoprotein E (ApoE) ε4 allele [3, 4],
has been much less investigated. In cultured cells
TREM2 R47H reduces ligand binding [8, 21–23]. Con-
sistent with a pivotal role in ligand binding, structural
analyses revealed that arginine 47 is required to stabilize
a conformation, which is capable to interact with ligands
such as ApoE and phosphatidylserine [24]. Furthermore
maturation of the R47H variant within the secretory
pathway may also be delayed [25]. In line with these
findings, expression of human TREM2 R47H in Trem2
knockout mice failed to rescue their phenotypes [14].
These findings may therefore be indicative of a
loss-of-function. In fact, very recently CRISPR/Cas9 gen-
erated mouse models expressing the R47H variant
within the endogenous Trem2 mouse locus revealed a
significant loss-of function [26, 27]. Trem2 R47H mice
exhibited reduced Trem2 upregulation in microglia,
reduced microgliosis, reduced clustering around amyloid
plaques and an overall reduction of Trem2 protein [26].
Haploinsufficiency of Trem2 was confirmed by a signifi-
cant reduction of Trem2 mRNA derived from the mutant
allele [26]. Thus heterozygous Trem2 R47H mice appear
to phenocopy a heterozygous knockout of Trem2.
We also independently generated Trem2 R47H
knock-in mice using the CRISPR/Cas9 technology and
reproduced haploinsufficiency of Trem2 in this model.
Moreover, we could demonstrate that reduced mRNA
stability due to a splicing error leads to a severe reduction
of Trem2 mRNA. However, aberrant splicing was mouse
specific and could not be observed in humans. Thus phe-
notypes associated with the R47H variant inserted into the
endogenous mouse locus may not allow conclusions on
the cellular mechanisms affected in humans.
Methods
Mice
Animal handling and animal experiments were per-
formed in accordance to local animal laws and housed
in standard cages in a specific pathogen-free facility on
a 12-h light/dark cycle with ad libitum access to food
and water.
Jax Trem2 R47H knock-in mice were purchased from
Jackson laboratory. In-house Trem2 R47H knock-in
mice were generated using CRISPR/Cas9 technology in
C57BL/6 N background. Both strains were housed and
bred in the same animal facility. To extract bone mar-
row, mice were first euthanized by CO2 followed by
cervical dislocation.
Generation of Trem2 R47H knock-in mice
Trem2 R47H knock-in mice (R47H ki mice) were gener-
ated by CRISPR/Cas9-assisted gene targeting in zygotes
as described previously [28, 29]. Briefly, pronuclear stage
zygotes were obtained by mating C57BL/6 N males with
superovulated C57BL/6 N females (Charles River).
Embryos were then microinjected into the male pronucleus
with an injection mix containing 25 ng/μl Cas9 mRNA,
12.5 ng/μl Trem2-specific sgRNA, and 25 ng/μl single-
stranded oligodeoxynucleotide (ssODN). Cas9 mRNA was
prepared from XbaI-linerized pCAG-Cas9v2-162A by in
vitro transcription using the mMESSAGE mMACHINE™
T7 ULTRA Transcription Kit (Thermo Fisher Scientific,
#AM1345) and purified using the MEGAclear™ Transcrip-
tion Clean-Up Kit (Thermo Fisher Scientific, #AM1908).
Trem2-specific sgRNA (protospacer: GAAGCACTG
GGGGAGACGCA) was prepared by IVT from pBS-T7-
sgTrem2 using the MEGAshortscript™ T7 Transcription
Kit (Thermo Fisher Scientific, #AM1354) and purified with
the MEGAclear™ Transcription Clean-Up Kit. The 130 nt
ssODN targeting molecule ssTrem2 R47H (5′- GGGC
ATGGCCGGCCAGTCCTTGAGGGTGTCATGTACTTA
TGACGCCTTGAAGCACTGGGGTCGACACAAAGCC
TGGTGTCGGCAGCTGGGTGAGGAGGGCCCATGCC
AGCGTGTGGTGAGCACACACGGT -3′), comprising
the G >A substitution (underlined) and three additional
silent mutations (bold), was synthetized by Metabion.
After microinjection, zygotes were cultured in KSOM
medium until they were transferred into pseudopregnant
CD-1 foster animals.
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Off-target analysis of Trem2 R47H mice
To identify putative off-target sites of the Trem2-specific
sgRNA, the online tool CRISPOR (http://crispor.tefor.n
et/) [30] was used. Predicted sites with a CFD score > 0.5
and an MIT score > 0.6 were chosen for off-target ana-
lysis. For analysis, genomic DNA of wildtype and hetero-
zygous mutant Trem2 R47H mice was isolated and the
loci were PCR amplified with primers flanking the puta-
tive cut sites. PCR amplicons were subsequently Sanger
sequenced using PCR amplification primers and the
traces compared to a reference sequence.
Bone marrow derived macrophages culture
Bone marrow derived macrophages (BMDM) were pre-
pared as previously described [31, 32]. Briefly, the bone
marrow cells were flushed out using advanced RPMI 1640
(Life Technologies). Cells were differentiated using ad-
vanced RPMI 1640 supplemented with 2 mM L-Glutamine,
10% (v/v)) fetal calf serum (FCS), 100 U/ml penicillin,
100 μg/ml streptomycin and 50 ng/ml murine M-CSF
(R&D System) for 7 days in non-cell culture treated dishes.
Microglia isolation
Microglia were isolated as previously described with
some modification [33]. Wild type and Trem2 R47H ki
mice were perfused with cold phosphate buffered saline
(PBS). Whole brain without the cerebellum was cut into
small pieces and gently homogenized by mechanical dis-
sociation in homogenization buffer (HBSS no calcium,
no magnesium, with phenol red; 15 mM HEPES, 0.6%
glucose). Homogenized cell suspensions were passed
through a 100 μm cell strainer. Cells were pelleted at
300 g for 10 min and the supernatant discarded. To re-
move myelin, the cell pellets were re-suspended in 22%
percoll (GE Healthcare) and centrifuged for 20 min at
900 g (acceleration 4, deceleration 0). Microglia were
purified from the pellet using MACS CD11b magnetic
beads according to manufacturer’s instructions. Briefly,
20 μl CD11b microbeads (Miltenyi) were incubated with
cell suspension for 15 min. After incubation, 500 μl
MACS buffer were added and cells were passed over a
pre-rinsed Miltenyi LS column attached to a magnetic field.
The column was washed three times with 500 μl MACS
buffer, removed from the magnetic field and CD11b
positive cells were washed out in 5 ml of MACS buffer.
Cell lysis and immunoblotting
To detect membrane bound Trem2, membrane fractions
were collected as previously described [32]. Briefly, cells
were lysed in hypotonic buffer (100 mM Tris-HCl, pH 7.4,
1 mM EDTA, 1 mM EGTA, pH 7.4) freshly supplemented
with a protease inhibitors cocktail (Sigma-Aldrich). Mem-
brane fractions were pelleted by centrifugation for 45 min
at 16,000 g at 4 °C. Membranes were lysed in STEN lysis
buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.6, 2 mM
EDTA, 1% Triton-X 100) on ice for 20 min. Equal
amounts of protein were mixed with Laemmli sample buf-
fer supplemented with β mercaptoethanol followed by by
SDS-PAGE. Proteins were transferred onto polyvinylidene
difluoride membranes (Amersham Hybond P 0.45 PVDF,
GE Healthcare Life Science) and blocked in 10%
I-BlockTM (Thermo Fisher Scientific) for 1 h. Monoclonal
antibody 5F4 (dilution 1:100) [32] was used to detect
Trem2.
iPSC generation
Ethical permission for this study was obtained from the
National Hospital for Neurology and Neurosurgery and
the Institute of Neurology joint research ethics commit-
tee (study reference 09/H0716/64). R47H heterozygous
fibroblasts were acquired with a material transfer agree-
ment between University College London and University
of California Irvine Alzheimer’s Disease Research Center
(UCI ADRC; M Blurton-Jones). Fibroblast reprogram-
ming was performed by episomal plasmid nucleofection
(Lonza) as previously described [34], using plasmids
obtained from Addgene (#27077, #27078 and #27080).
Nucleofected cultures were transferred to Essential 8
medium (Life Technologies) after 7 days in vitro (DIV)
and individual colonies were picked after 25–30 DIV. All
iPSCs were maintained and routinely passaged in Essential
8 medium. Karyotype analysis was performed by The
Doctors Laboratory (London, UK). Control iPSC lines
used in this study are as follows: CTRL1 (kindly provided
by Dr. Selina Wray, UCL Institute of Neurology); CTRL2
(SBAD03, Stembancc); CTRL3 (SFC840, Stembancc);
CTRL4 (BIONi010-C, EBiSC).
iPSC-derived microglia-like cells (iMG)
Using previously described protocols, iPSC-derived
microglia-like cells (iMG) were generated [35, 36].
Day 0: iPSC lines were cultured to 60% confluency in
E8 medium on vitronectin-coated 6-well plates. Cells
were washed with PBS (w/o Ca2+/Mg2+), followed by
trypLE digestion (1 ml/well; 4 min at 37 °C). The solu-
tion was added to 4 volumes of PBS (w/o Ca2+/Mg2+),
and triturated to a single cell suspension. The suspen-
sion was centrifuged for 3 min at 300 g and the cell
pellet resuspended in 1 ml EB differentiation medium
(Adapted from [36]; EBdiff; Essential 8, 50 ng/ml
BMP-4, 50 ng/ml VEGF, 20 ng/ml SCF, and 10 μM
Y-27632). Cells were counted, and resuspended in
EBDiff medium to a density of 105 cells/ml. To generate
embryoid bodies (EBs), 100 μl of the suspension was
added to 96 well ultra-low attachment round bottom
tissue culture plates (Corning), centrifuged at 115 g for
3 min, and transferred to a tissue culture incubator at
37 °C with 5% CO2.
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Day 2: 50 μl of EBdiff medium was added to each well.
Day 3: Dense EBs were formed and collected with a
P1000 Gilson pipette into a sterile 15 ml tube, and left
to settle. The spent EBdiff medium was discarded and
10 ml of myeloid differentiation medium (Mdiff; X-VIVO
15 medium (Lonza), 1X Glutamax (Life Technologies),
100 U Penicillin/Streptomycin (Life Technologies), 50 μM
β-mercaptoethanol (Life Technologies), 100 ng/ml MCSF
(Peprotech), and 25 ng/ml IL-3 (Cell Guidance Systems))
added. Approximately 150 embryoid bodies (1.5 × 96 well
plates) were transferred to a 175 cm2 flask containing a
further 20 ml of Mdiff medium.
Day 9–11: Mdiff medium (30 ml) was added, to avoid
acidosis, being careful not to disturb the EBs.
Day 26: Cells were collected from the medium for
myeloid marker analysis.
Day 33: Once a week, 1/2 of the Mdiff medium/flask
containing budded myeloid cells was collected through a
40 μm cell strainer (Falcon, Corning), replacing the
collected medium with fresh Mdiff. The myeloid cell
suspension was centrifuged for 3 min at 300 g and the
cell pellet resuspended in 1 ml microglial differentiation
medium (Adapted from [35]; MGdiff; DMEM/F12
HEPES no phenol red, 2% ITS-G (Life Technologies),
1% N2 supplement (Life Technologies), 200 μM mono-
thioglycerol (Sigma), 1X Glutamax, 1X NEAA (Life
Technologies), 5 μg/ml Insulin (Sigma), 100 ng/ml IL34
(Peprotech), 25 ng/ml MCSF and 5 ng/ml TGFβ1
(Peprotech), filtered through a 0.22 μm syringe filter.
Cells were counted and plated in MGdiff, and medium
replaced every 3–4 days.
Day 46: MGdiff medium was replaced with microglial
maturation medium (MGmat: MGdiff + 100 ng/ml
CD200 (Generon), and 100 ng/ml CX3CL1 (Peprotech))
for 4 days to generate iMG.
Isolation of human blood derived-monocytes
Monocytes were obtained from blood through centrifuga-
tion with Histopaque (Sigma) to isolate peripheral blood
mononuclear cells followed by separation and purification
with CD14-conjugated magnetic beads (Miltenyi). Periph-
eral blood monocytes (PBM) were matured into
monocyte-derived macrophages (hMacs) in X-VIVO 15
medium with 1% Glutamax, 100 U Penicillin/Streptomycin,
and 100 ng/ml MCSF for 7 days.
Microglia signature gene array
A custom gene array based on published microglial ex-
pression data [35, 37–39] was used to confirm a micro-
glial signature in our iMG cultures (TaqMan Array
Plate 32 plus Candidate Endogenous Control Genes;
Thermo Fisher Scientific). Complementary DNA was
generated from iMG, iPSC-derived microglial-like cells
[36], and human monocyte-derived macrophages
(hMacs) RNA samples using the High-Capacity
RNA-cDNA kit (Life Technologies), according to the
manufacturer’s instructions. Human primary microglia
cDNA was also analyzed as a control sample (ScienCell).
Quantitative PCR were conducted on the Mx3000p
qPCR system with MxPro qPCR software (Stratagene)
using TaqMan Gene Expression Mastermix (Thermo
Fisher Scientific). Heat maps were generated with the
gplots [40] and d3heatmap [41] packages in R.
Microglial gene signature primer details:
Gene name Primer ID
18 s rRNA Hs99999901_s1
GAPDH Hs99999905_m1
HPRT Hs99999909_m1
GUSB Hs99999908_m1
APOE Hs00171168_m1
C1QA Hs00706358_s1
C1QB Hs00608019_m1
ITGAM Hs00167304_m1
CSF1R Hs00911250_m1
CX3CR1 Hs01922583_s1
GAS6 Hs01090305_m1
GPR34 Hs00271105_s1
AIF1 Hs00610419_g1
MERTK Hs01031979_m1
OLFML3 Hs01113293_g1
PROS1 Hs00165590_m1
SALL1 Hs01548765_m1
SLCO2B1 Hs01030343_m1
TGFBR1 Hs00610320_m1
TMEM119 Hs01938722_u1
TREM2 Hs00219132_m1
BIN1 Hs00184913_m1
CD33 Hs01076282_g1
SPI1 Hs02786711_m1
HEXB Hs01077594_m1
ITM2B Hs00222753_m1
C3 Hs00163811_m1
A2M Hs00929971_m1
C1QC Hs00757779_m1
RGS1 Hs01023772_m1
FTL Hs00830226_gH
P2RY12 Hs01881698_s1
Immunocytochemistry
Cells were fixed in 4% PFA/sucrose in PBS for 20 min at
room temperature (RT), quenched with 50 mM NH4Cl
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in PBS for 10 min at RT, and permebalized with 0.2%
Triton X-100 in PBS for 5 min at RT. Blocking was per-
formed with 5% normal goat serum (NGS) in PBS for
30 min. Primary antibodies were diluted in 5% NGS/PBS
and incubated at RT for 2 h, followed by PBS washes and
incubation with corresponding secondary antibodies for 1 h
at RT in the dark, with gentle rocking. Nuclei were coun-
terstained during mounting using Vectorshield with DAPI
(4′, 6-diamidino-2-phenylindol; Vector Labs). Fluorescence
microscopy was performed on a Zeiss Axioskop 2 micro-
scope and Axiovison software (Zeiss, v4.8). Confocal
microscopy was performed on a Zeiss LSM 710 confocal
microscope using Zen software (Zeiss, Version 2012), and
all images were processed with Image J1.51 K (https://
imagej.nih.gov/ij/). The following antibodies were used:
mouse anti-CD68 (1:100, DAKO), rabbit-anti-P2YR12
(1:200, Atlas Antibodies), mouse-anti-β-Actin (1:500,
Sigma), mouse-anti-EZR (1:250, Atlas Antibodies), goat
anti-rabbit Alexafluor488 (1:500, Life Technologies),
goat-anti-mouse Alexafluor568 (1:500, Life Technologies).
Cellular splicing assay
Human and mouse Trem2 genomic fragments encoding
exon 1, intron 1, exon 2, and a FLAG tag were synthesized
by Integrated DNA Technologies. The following primer
sets were used for vector cloning: EcoRV-Hs TREM2-Fw
(GGATATCCGGGCAGCGCCTGACATGCCTG) and No
tI-Hs TREM2-Rv (ATGCGGCCGCTTAGGATTACAA
GGATGACGACGATAAG); HindIII-Mm Trem2 Fw (CC
CAAGCTTGGGGCGCCTACCCTAGTCC) and XohvI-
Mm Trem2-Rv (CCGCTCGAGCGGCTACTTGTCGTCA
TCG). The amplified fragments were digested by EcoRV/
NotI or HindIII/XohI and the digested fragments were
inserted into pcDNA3.1 (+) (Invitrogen). The mutations
were introduced in the human and mouse minigene using
the Quikchange™ site-directed mutagenesis kit (Agilent).
The following mutants were generated:
(1) R47H is the G > A variant alone encoding arginine;
(2) R47HTCA corresponds to sequence variants
expressed by the in-house generated Trem2 R47H
ki mice (GA > TC, G > A, G > A; also see Fig. 4b);
(3) R47HAA represents the Trem2 R47H ki mice
generated by Jackson Laboratory (G > A, G > A, C >
A; also see Fig. 4b);
(4) TC are the silent mutations in in-house generated
Trem2 R47H ki mice (GA > TC)
(5) AA are the silent mutations in Jax R47H ki mice
(G > A, C > A).
(6) R47HT represents Trem2 R47H ki mice generated
by Cheng Hathaway et al. [26]
For the cellular splicing assay 8 × 105 HEK293 cells
were seeded in 6-well plates with Dulbecco’s Modified
Eagle Medium (Life Technologies) supplemented with
GlutaMAX™, 10% (v/v) FCS, 100 U/ml penicillin,
100 μg/ml streptomycin and cultured overnight. Cells
were transfected with 3 μg of plasmids to express human
or mouse Trem2 minigenes using 6 μl lipofectamine
2000 according the manufacturer’s instructions (Thermo
Fisher Scientific). Transfected cells were cultured in nor-
mal medium for 48 h and collected for RNA extraction
using RNeasy Mini Kit (Qiagen) according the manufac-
turer’s instructions. The RNA was used for Reverse
transcription polymerase chain reaction (RT-PCR).
Reverse transcription polymerase chain reaction
1 μg of total RNA was transcribed into cDNA using
SuperScript IV reverse transcriptase and oligo dT
(Thermo Fisher Scientific). 2 μl of cDNA was used as
template and amplified by polymerase chain reaction
(PCR) with GoTaq DNA polymerase (Promega) according
the manufacturer’s instructions. The reaction condition
and primer sequences are listed in Table 1. The PCR
products were loaded into 2% agarose gel with GelRed™
(Biotium) for DNA visualization.
Quantitative real-time polymerase chain reaction
RNeasy Mini Kit (Qiagen) was used for total RNA
isolation according the manufacturer’s instructions. 1 μg
of total RNA was transcribed into cDNA using
SuperScript IV reverse transcriptase and oligo dT
(Thermo Fisher Scientific). RNA levels of human and
mouse Trem2 and Tyrobp were analyzed by Taqman®
real-time PCR using the 7500 Fast real-time PCR system
(Applied Biosystems). For endogenous controls Gusb
(Mm01197698_m1, Thermo Fisher Scientific) and
Hsp90ab1 (Mm00833431_g1, Thermo Fisher Scientific)
or GUSB (Hs00939627_m1, Thermo Fisher Scientific)
and HSP90AB1 (Hs03043878_g1, Thermo Fisher Scientific)
were used. Probes that target mouse Trem2 and Tyrobp
Table 1 Primers and PCR conditions used for detecting splice pattern (Forward: Fwd; Reverse: Rev)
Name Sequence Reaction condition
MmTrem2 Fwd GCTCAATCCAGGAGCACAGT 95 °C 1 min; (95 °C 30s, 65 °C 15 s, 72 °C 1 min) *35 cycle; 72 °C 10 min
MmTrem2 Rev TCTGACACTGGTAGAGGCCC
HsTREM2 Fwd GCCTGACATGCCTGATCCTC 95 °C 1 min; (95 °C 30s, 65 °C 15 s, 72 °C 1 min) *35 cycle; 72 °C 10 min
HsTREM2 Rev AGGACCTTCCTGAGGGTGTC
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are Mm04209424_g1, Mm04209423_g1, Mm01273682_g1,
Mm00449152_m1 (Thermo Fisher Scientific). Probes
that target human TREM2 and TYROBP are Hs01010
721_m1, Hs01003899_m1, Hs00182426_m1 (Thermo
Fisher Scientific). For allele specific mRNA expression
custom made primers and probes were designed. The
primer pair for mouse Trem2 is: CCTTGAGGGTGTCA
TGTACTTAT and TCCCATTCCGCTTCTTCAG. The
probes for the mouse wild-type allele and R47H allele
are /5HEX/CCTT+G + C + GT + CT + CC/3IABkFQ/
(+, lock nucleic acid) and /56-FAM/CTT+T+G+T+GT
+C+GA+C/3IABkFQ/, respectively (Integrated DNA
Technologies). The primer pair for human TREM2 is
ACAAGTTGTGCGTGCTGA and ATGACTCCATGAA
GCACTGG. The probes for the human wild-type allele
and the R47H allele are /5HEX/CTT+G+C+GCCT
+CC/3IABkFQ/ and /56-FAM/TT+G+T+GC+CT +
CC/3IABkFQ/, respectively (Integrated DNA Technolo-
gies). The probes and primers were mixed in 1:2 ratios
for quantitative PCR reaction.
cDNAs were diluted 1:5 with H2O and 9 μl of diluted
cDNA together with 1 μl of primer probe mix, 10 μl of
Taqman® master mix (Thermo Fisher Scientific) were
used in one 20 μl reaction.
Results
Reduced mRNA and protein level in Trem2 R47H knock-in
mice
The rare TREM2 variant rs75932628-T encodes a histi-
dine instead of arginine at position 47 (R47H) and
increases the risk for AD around three-fold [3, 4]. The
DNA and amino acid sequence around arginine at pos-
ition 47 is highly conserved across different mammalian
species (Fig. 1a and b). To study the impact of this vari-
ant on TREM2 function in microglia in vivo we gener-
ated Trem2 R47H knock-in mice (R47H ki mice) by
introducing a G > A mutation using the CRISPR/Cas9
technology (Fig. 1c). Two silent mutations were add-
itionally introduced (GA > TC) to create a SalI restric-
tion site for genotyping (Fig. 1c). In addition a silent G >
A mutation was generated to block the protospacer-ad-
jacent motif (PAM) to allow higher gene editing effi-
ciency (Fig. 1c). The predicted potential off-target sites
were analyzed. An off-target event with a Δ10-Indel
mutation was identified at an intragenic region on
chromosome 11 (Additional file 1: Figure S1, putative
off-target #2). The founder mouse was back-crossed to
C57BL/6 N, and off-spring with positive Trem2 R47H ki
but negative off-target #2 (i.e ID-7-1; ID-7-2; ID-7-4)
were used for establishing the mouse line. Expression of
total Trem2 mRNA as well as both Trem2 mRNA tran-
scripts (NM_031254.3 and NM_001272078.1), encoding
either membrane bound Trem2 or a truncated soluble
version were validated in brain. Interestingly, total
Trem2 mRNA including both Trem2 transcripts was
significantly reduced in a gene dose-dependent manner,
whereas mRNA expression of Tyrobp (NM_011662), the
adaptor protein of Trem2 [42], remained unchanged
(Fig. 1d). Using allele specific qPCR we confirmed that
expression of the R47H allele was selectively reduced
compared to the wt allele in heterozygous R47H ki mice
(Fig. 1e and Additional file 2: Table S1).
To confirm decreased Trem2 expression on protein
level, we purified microglia from wild-type (wt), heterozy-
gous (het), and homozygous (hom) R47H ki mice and
performed western blotting of membrane fractions.
Membrane-bound Trem2 showed a gene dose-dependent
reduction (Fig. 1f).
Reduced Trem2 R47H mRNA and protein expression
was further confirmed in bone marrow derived
macrophages (BMDM). Consistent with our findings in
brain and microglia, mRNA of both Trem2 transcripts
decreased in a gene dose dependent manner whereas
mRNA of Tyrobp remained unchanged (Fig. 1g).
Furthermore, immature and mature Trem2 as well as
soluble Trem2 (sTrem2) were also reduced in a gene
dose dependent manner (Fig. 1h).
To exclude that reduced Trem2 mRNA and protein
expression is artificially caused by the introduction of
the three silent mutations, we analyzed Trem2 R47H
knock-in mice generated by Jackson laboratory (Jax
R47H ki mice). In addition to the target variant R47H,
these mice harbor two silent mutations (Fig. 2a). One of
the silent mutations is a G > A exchange to block the
PAM sequence exactly like in the mice generated within
our laboratory. The second silent mutation C > A is only
present in the Jax R47H ki mice (Fig. 2a). We investi-
gated Trem2 mRNA and protein levels using homozy-
gous Jax R47H ki mice and their wt counterparts. Again,
mRNA from total Trem2 as well as from both tran-
scripts of Trem2 decreased in brains of homozygous ki
mice whereas mRNA expression of Tyrobp remained
unchanged (Fig. 2b). Western blotting of membrane
fractions from BMDM from the Jax R47H ki mice also
confirmed a significant reduction of membrane bound
and soluble Trem2 (Fig. 2c). Thus reduction of mRNA
and protein levels in Trem2 R47H ki mouse was
confirmed in two independent mouse models.
Aberrant splicing of exon1/2 in Trem2 R47H knock-in
mice
Next we searched for the cellular mechanism responsible
for the substantial reduction of the Trem2 R47H mRNA
in the two mouse models. Since nonfunctional mRNAs
are rapidly removed by mRNA surveillance systems [43],
we studied splicing of the first intron which separates
exon 2 containing the R47H variant from exon
1 harboring the translation initiation site and upstream
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Fig. 1 Trem2 mRNA and protein are reduced in a novel Trem2 R47H knock-in mouse model. a and b Evolutionary conservation of TREM2 at the
DNA (a) and protein (b) level. c Strategy to generate Trem2 R47H knock-in (R47H ki) mice indicating the protospacer region (green), protospacer
adjacent region (PAM, purple), and the introduced nucleotide changes (orange or red). The restriction site for SalI is underlined. d Trem2 and
Tyrobp mRNA levels in brains from R47H ki mice. TaqMan probes for the exon 4/5 boundary were used to detect total Trem2 mRNA. TaqMan
probes for the Trem2 exon 3/4 boundary were used for isoform discrimination. (N = 3, +/-SEM, one way ANOVA, Bonferroni-corrected pair-wise
post hoc tests, total Trem2 WT vs. Het p = 0.0002, WT vs. Hom p < 0.0001; Trem2 isoform 1 WT vs. Het p = 0.0029, WT vs. Hom p < 0.0001; Trem2
isoform 2 WT vs. Het p = 0.0031, WT vs. Hom p = 0.0002. n.s. Non-significant). e Allele specific Trem2 mRNA expression in heterozygous
R47H ki mice. Customized probes were against Trem2 R47H and its neighbor region (see also Methods). (N = 3, +/-SEM, unpaired t test,
p < 0.0001). f Trem2 protein expression in microglia isolated from Trem2 wt or R47H ki mice. (N = 3,+/-SEM, one way ANOVA, p < 0.0001,
Bonferroni-corrected pair-wise post hoc tests, WT vs. Het p = 0.0005, WT vs. Hom p < 0.0001). g Trem2 and Tyrobp mRNA levels in bone
marrow derived macrophages (BMDM) isolated from Trem2 wt and R47H ki mice. (N = 3, +/-SEM, one way ANOVA, Bonferroni-corrected
pair-wise post hoc tests, Trem2 WT vs. Het p = 0.0002, WT vs. Hom p < 0.0001; Trem2 isoform 1 WT vs. Het p < 0.0001, WT vs. Hom p < 0.0001;
Trem2 isoform 2 WT vs. Het p = 0.0008, WT vs. Hom p < 0.0001. n.s. Non-significant.) h Expression levels of membrane bound and soluble Trem2
(sTrem2) protein in BMDM isolated from Trem2 wt or R47H ki mice. (N = 3, +/-SEM, one way ANOVA, Trem2 p = 0.0003, Bonferroni-corrected pair-wise
post hoc tests, WT vs. Het p = 0.0026, WT vs. Hom p = 0.0002, sTrem2 p = 0.0007, WT vs. Het p = 0.0469, WT vs. Hom p = 0.0005)
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untranslated sequences. Using RT-PCR with primer pairs
against the 5′ end of exon 1 and the 3′ end of exon 2, we
compared the splicing patterns of Trem2 in R47H ki and
wt mice (Fig. 3a). A single splicing product of the expected
length (465 base pairs) was obtained from wt Trem2
mRNA (Fig. 3b). Surprisingly, an additional smaller spli-
cing product (346 base pairs) was observed in Trem2
R47H heterozygous mice, which was even more abundant
in Trem2 R47H homozygous mice (Fig. 3b) while at the
same time the larger splicing product was reduced in a
gene dose dependent manner (Fig. 3b). This suggests aber-
rant splicing of Trem2 pre-mRNA derived from the mu-
tant allele. To independently confirm aberrant splicing,
we investigated the Jax R47H ki mice described in Fig. 2.
Again, we found an additional smaller RT-PCR product in
mutant but not wt mice (Fig. 3c). Furthermore, the larger
splicing product was reduced in homozygous ki mice
(Fig. 3c). Thus aberrant splicing of R47H pre-mRNA
occurs in two independent mouse models. DNA sequen-
cing of the splicing products revealed correct splicing of
exon 1 and exon 2 in wt mice and to a lesser extent also in
the ki mice (Fig. 3d). However, DNA sequencing of the
additional shorter RT-PCR product of both mutant mice
revealed that 119 base pairs were deleted at the 5′ end of
exon 2 (Fig. 3d and Additional file 3: Figure S2). The dele-
tion leads to a frame shift and a premature stop codon in
exon 2 (Fig. 3d), which may lead to nonsense mediated
mRNA decay and thus explain the consistent reduction of
the mutant mRNA in both mouse models.
The R47H variant does not affect splicing and mRNA
levels in humans
To directly compare the splicing pattern of mouse and
human TREM2 R47H, we expressed mouse or human
TREM2 minigenes containing exon 1, intron 1, and exon 2
in human embryonic kidney 293 cells (HEK 293) (Fig. 4a).
To separately investigate the disease causing TREM2
R47H variant and the silent mutations, we introduced the
corresponding sequence variants either alone or together
(Fig. 4b). Upon expression of the minigene encoding the
mouse Trem2 sequence, we observed miss-splicing in-
duced by the R47H variant alone (R47H) (Fig. 4c). Similar
aberrant splicing was observed when the two silent muta-
tions of the Jax R47H ki mice were expressed in addition
to the R47H variant (R47HAA), whereas introduction of
the two silent mutations alone (AA) did not affect splicing
(Fig. 4c). Moreover, when the three silent mutations used
to generate our in-house mouse model were combined
with the R47H (R47HTCA), a striking increase of aberrant
splicing was observed. When we only introduced the
unique TC mutations used to generate our mouse model
(TC) we also observed impaired splicing (Fig. 4c),
a
b
c
Fig. 2 Trem2 haploinsufficiency in an independent R47H knock-in mouse model provided by Jackson laboratories. a DNA sequence comparison
of in-house made Trem2 R47H ki mice (R47H ki mice) and Jax Trem2 R47H ki mice (Jax R47H ki mice). b Trem2 and Tyrobp mRNA levels in brains
of wt or Jax R47H ki mice. (N = 3, +/-SEM, unpaired t test, Total Trem2 p = 0.0005; Trem2 isoform1 p = 0.0002; Trem2 isoform2 p = 0.0001. n.s.
Non-significant.). c Expression levels of membrane bound and soluble Trem2 (sTrem2) protein in bone marrow derived macrophages (BMDM)
isolated from Trem2 wt or Jax R47H ki mice (N = 3, +/-SEM, unpaired t test, Trem2 p = 0.0016, sTrem2 p = 0.0433)
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suggesting that R47H and TC together display synergistic
effects on aberrant splicing. This demonstrates that the
R47H variant by itself is sufficient to induce aberrant spli-
cing, but enhanced miss-splicing upon the addition of si-
lent mutations implies that this genomic region is very
sensitive for splicing errors induced by minor changes
within the pre-mRNA sequence. Finally, we also investi-
gated if the mutations introduced into the mouse genome
by Cheng-hathaway et al. [26] affect pre-mRNA splicing of
Trem2. Very similar to our R47H ki mice and those gener-
ated by the Jackson Laboratories, the mutations introduced
by Cheng-hathaway and colleagues (R47HT) caused aber-
rant splicing (Fig. 4c), which is consistent with the haploin-
suffciency also observed in this model [26].
To prove if this is also true for human TREM2, we
investigated the same TREM2 variants in human minigene
constructs (Fig. 4a, b and d). Surprisingly, our results
demonstrate that neither the R47H variant alone or in
combination with the silent mutations used to generate the
ki mouse models affected correct exon1/2 splicing (Fig. 4d).
This suggests that only the mouse gene locus is vulnerable
for aberrant splicing upon introduction of these sequence
variants and implies that the R47H mutation does not
affect splicing and mRNA levels in humans.
To provide direct evidence for this prediction, we
investigated exon 1/2 splicing in humanized TREM2 mice
generated by ectopic expression of the human wt or R47H
mutant TREM2 locus in Trem2−/− mice [14]. Using the
same RT-PCR strategy as described above (Fig. 3a), we
could only detect the correctly spliced exon 1 and 2 but
no aberrantly spliced additional products (Fig. 5a).
Similarly, in human induced pluripotent stem cell
(iPSC)-derived microglia-like cells (iMG) with the wt
TREM2 allele or heterozygous for the TREM2 R47H
variant (Additional file 4: Figure S3) we also detected only
the correctly spliced exon 1 and 2 (Fig. 5b). Furthermore,
no aberrant splicing was detected in AD cases carrying
one R47H mutant allele (Fig. 5c). Direct sequencing dem-
onstrated correct exon1/2 splicing in human iMG and in
AD cases. Lack of aberrant splicing of human TREM2
R47H is consistent with no reduction of total TREM2
mRNA in iMG with one R47H allele (Fig. 5d). In addition,
using allele specific qPCR we confirmed that the
expression of the R47H allele is comparable to wt in iMG
(Fig. 5e and Additional file 5: Table S2), and in human
brain (Fig. 5f and Additional file 5: Table S2). Taken to-
gether, aberrant splicing of R47H mutant pre-mRNA is
not observed in humans and consequently no haploinsuffi-
ciency of TREM2 could be detected.
Discussion
Most functional studies of TREM2 have so far been
performed with either total loss-of-function models or
by studying the TREM2 T66M mutation [7, 8, 11–13,
19, 20, 44, 45], which is associated with an FTD-like syn-
drome. Homozygous mice expressing the Trem2 T66M
a
d
b c
Fig. 3 Aberrant splicing of exon1/2 in two independent Trem2 R47H knock-in mice. a Schematic representation of exon/intron boundaries of
Trem2 and the strategy used to investigate exon 1/2 splicing. b RT-PCR mediated amplification of splicing products generated by R47H ki mice. c
RT-PCR mediated amplification of splicing products generated by Jax R47H ki mice. d DNA and amino acid sequence of the two splice
products identified. Fwd: Forward; Rev: Reverse
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variant phenocopy a number of functional deficits also
observed upon total loss of the Trem2 encoding gene
[11]. These include delayed resolution of inflammation
upon lipopolysaccharide stimulation, reduced phagocytic
activity, reduced microglial activation during physio-
logical ageing and neurological insults, reduced cerebral
blood flow, reduced cerebral brain glucose metabolism,
impaired chemotaxis and clustering of microglia around
amyloid plaques [11]. However, much less is known
about the functional impact of the TREM2 R47H vari-
ant, which is associated with a high risk for AD similar
to that caused by the ApoE ε4 allele [3, 4, 46]. In vitro
studies suggested reduced binding of Aβ oligomers, ApoE,
and phosphatidylserine due to structural alterations in
TREM2 [8, 21–24]. Furthermore maturation of the R47H
variant within the secretory pathway may also be delayed
[25]. Expression of human TREM2 R47H in Trem2
knockout mice failed to rescue the knockout phenotypes
again supporting the notion that TREM2 is protective and
that TREM2 variants associated with neurodegenerative
diseases may cause a loss-of-function [14]. Trem2 R47H
knock-in mice expressing this variant under physiological
conditions resulted in phenotypes that were compatible
with a loss-of function [26]. Cheng-Hathaway et al.
a
b
c
d
Fig. 4 Aberrant splicing of Trem2 variants containing the R47H mutation with and without additional mutations used to create three different
R47H ki mice. a The minigene construct used to investigate exon1/2 splicing of the Trem2 variants shown in (b). b Sequence alignment of Trem2
variants investigated for aberrant splicing. c Exon 1/2 splicing of mouse Trem2 variants described in (b). d Exon 1/2 splicing of human TREM2
variants described in (b). Note that only mouse transcripts undergo aberrant splicing. EV: empty vector
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reported that Trem2 R47H heterozygous mice showed
reduced Trem2 expression in microglia close to amyloid
plaques, reduced microglial proliferation, reduced dense
core plaques and increased neuritic dystrophy [26]. These
phenotypes were associated with reduced Trem2 mRNA ex-
pression [26]. Similarly, Sudom et al. reported reduced
Trem2 protein expression in brain as well as reduced
sTrem2 in plasma from R47H knock-in mice [24]. All
together, this suggests that the AD-associated Trem2 R47H
variant is also associated with a loss-of-function. However,
while the T66M mutation causes a loss-of-function due to
retention of the misfolded mutant protein within the endo-
plasmatic reticulum [11, 25], the R47H mutation appears to
cause haploinsufficiency due to reduced mRNA levels [26].
We generated a similar mouse model using the CRISPR/
Cas9 technology. Consistent with published findings, our
mouse model also showed reduced Trem2 mRNA and pro-
tein levels. Furthermore, similar findings were made using
an independent mouse generated by Jackson Laboratories.
We therefore searched for a joined cellular mechanism,
which may be involved in the significant reduction of Trem2
mRNA and protein in both mouse models. Surprisingly, we
found that the introduction of the R47H variant by itself but
even more so the introduction of additional silent mutations
caused aberrant splicing. Direct sequencing of the aberrant
splicing product revealed that it lacks 119 base pairs. Close
inspection of the sequence of the alternative splice product
revealed that a cryptic splice acceptor site within the exon 2
was activated. This leads to the elimination of parts of exon
2 resulting in a splicing product containing a premature
stop codon. It is well known that such aberrant mRNAs are
rapidly degraded by nonsense-mediated mRNA decay [47].
Note that the TaqMan probes used for detecting Trem2
mRNA were either bound to exon 3/4 or exon 4/5 bound-
ary (Fig. 1d) thus they detect both the full length functional
Trem2 mRNA and the aberrantly spliced shorter variant.
Therefore, the apparent degree of reduction for Trem2
mRNA and protein is not equal (Fig. 1d and f). However,
we cannot fully exclude the possibility that the R47H variant
may also affect mouse Trem2 protein stability.
The mRNA reductions caused by aberrant splicing,
which were consistent in two independent mouse models,
led us to investigate if aberrant exon 2 splicing in humans
also leads to TREM2 haploinsufficiency. We found that
TREM2 mRNA levels and splicing patterns were both
normal in iPSC-derived human microglia-like cells and in
patient brains with the TREM2 R47H variant. Further-
more, cellular splicing assays using minigene constructs
demonstrate that the R47H variant induced abnormal spli-
cing only occurs in mice but not in humans. Thus, both
the R47H variant as well as additionally introduced silent
variants cause a mouse-specific reduction of Trem2
mRNA. Therefore, these findings cannot be translated to
humans calling for novel humanized R47H mouse models.
a b c
d e f
Fig. 5 Normal exon 1/2 splicing of human TREM2 pre-mRNA encoding the R47H variant. a Normal splicing of human TREM2 upon ectopic
expression of the human wt or R47H mutant TREM2 locus in Trem2−/− mice. b Normal exon 1/2 splicing of Trem2 in human induced pluripotent
stem cell (iPSC)-derived microglia-like cells (iMG) with the wt TREM2 allele or heterozygous for the TREM2 R47H variant. c No aberrant splicing of
the R47H variant in an AD case carrying one R47H mutant allele. d No reduction of total TREM2 mRNA in iMG with one R47H allele. (N = 4,
+/-SEM, unpaired t test, non-significant.) e Allele specific qPCR demonstrates that the expression of the R47H allele is comparable to the wt allele
in iMG. (N = 7, +/-SEM) f Allele specific qPCR demonstrates that the expression of the R47H allele is comparable to wt allele in human brains
derived from R47H carriers. (N = 2). Customized probes were against Trem2 R47H and its neighbor region (see also Methods)
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Conclusions
The AD-associated Trem2 R47H variant in combination
with silent mutations introduced by the CRISPR/Cas9
technology causes mouse specific aberrant splicing of exon
2, which leads to an alternative Trem2 mRNA containing
a premature stop codon. The observed significant reduc-
tion of Trem2 mRNA and protein in R47H ki mice is most
likely the consequence of nonsense-mediated mRNA
decay of the aberrant transcript and is not observed in hu-
man systems. Thus, functional data derived from Trem2
R47H knock-in mice cannot be translated to humans.
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Indel mutation. b Sanger sequencing results of Trem2 R47H positive off-
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Indel allele was inherited to animals ID-7-3 und ID-7-12 that were excluded
from any further breedings and experiments. (PDF 201 kb)
Additional file 2: Table S1. Allele specific quantitative PCR for Trem2
R47H knock-in mice (PDF 92 kb)
Additional file 3: Figure S2. Sequence of the aberrantly spliced murine
Trem2 mRNA. Trem2 gene sequence. Exon in black; intron in green; //
indicates splicing sites. (PDF 93 kb)
Additional file 4: Figure S3. iMG differentiation and validation. a
Schematic of the in vitro differentiation of iPSC-derived microglia-like cells
(iMG). (i): Human iPSCs are grown in feeder free conditions with no spon-
taneous differentiation. Scale bar: 250 μm. (ii): Embryoid bodies are
formed in the presence of 3 factors SCF, BMP4, and VEGF; Scale bar:
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MCSF growth factors for 3–4 weeks, then stained for classic myeloid/
macrophage markers CD68. Scale bar: 50 μm. (iv): Further differentiation
to microglia-like cells that positive for microglial markers P2RY12. Scale
bar: 20 μm. (v): Addition of the two final factors (CD200 and CX3CL1) ma-
tures the iMG. Scale bar: 20 μm. b Heat map showing mRNA expression of
a microglial gene signature in iMG, human monocyte-derived macrophages
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